Research use only: what the label means in the UK and US

“For research use only” is a sentence a seller prints on a label. It is not a licence, an exemption or a legal status in the UK or the US. In both countries the question regulators ask is what a product is actually for, judged by how it is presented, sold and used, and a disclaimer is only one piece of that evidence.

This matters because most peptides discussed online are sold this way. Here is what the phrase does and doesn’t do on each side of the Atlantic, and where legitimate routes such as prescribing and pharmacy compounding fit in.

What the phrase is trying to do

A genuine research chemical is sold to laboratories for experiments: cell work, animal studies, analytical reference. Medicines law is aimed at products for people. The label tries to place a product in the first group so the second set of rules doesn’t apply.

That works only if it’s true. A vial sold beside bacteriostatic water, with dosing charts and before-and-after stories, is not a laboratory reagent in any meaningful sense, and regulators in both countries say so.

The UK: what makes something a medicine

The Human Medicines Regulations 2012 define a medicinal product in two limbs [1]. The first covers any substance “presented as having properties of preventing or treating disease in human beings”. The second covers any substance that may be used in or given to people to restore, correct or modify a physiological function through a pharmacological, immunological or metabolic action.

Either limb is enough. A peptide can become a medicine because of how it is marketed, or because of what it does in the body, whatever the label says.

Once something is a medicinal product, the rules are short and strict. Nobody may sell or supply, or offer to sell or supply, a medicinal product without a marketing authorisation or one of a few listed equivalents [2]. Prescription-only medicines may only be sold or supplied against a prescription from an appropriate practitioner [3].

A disclaimer carries some weight, but not much. The MHRA’s own guidance on borderline products summarises European case law that still shapes its approach: a statement that a product is not medicinal “is persuasive evidence” a court may consider, “but is not in itself conclusive” [4]. The same guidance says the MHRA decides case by case, looking at all of a product’s characteristics [4].

There is a real research exemption. The regulations don’t apply to medicinal products intended for research and development trials, although clinical trials on people have their own separate regime [4]. That covers genuine research. It doesn’t cover selling injectable vials to the public.

What enforcement looks like

The MHRA’s Criminal Enforcement Unit is active in this area. In May 2026 it announced two arrests after recovering around 12,000 doses of unlicensed weight-loss medicines, including retatrutide and tirzepatide as well as other peptide products, from a property near Northampton. The suspects were arrested on suspicion of offences under the Human Medicines Regulations 2012 [5].

The UK’s legitimate route for unlicensed medicines

The UK does allow unlicensed medicines in some circumstances. Regulation 167 lets a “special” be supplied without a marketing authorisation in response to an unsolicited order, made to the specification of a doctor, dentist or certain other prescribers, for a patient they are directly responsible for, to meet that patient’s special needs [4]. That route runs through a prescriber who takes responsibility for the patient. It isn’t a loophole for retail sales.

The US: intended use decides

US law turns on a similar idea. Under federal regulations, “intended use” means the objective intent of the people responsible for a product, which can be shown by their statements, by the product’s design or composition, or by the circumstances of its sale, including labelling claims and advertising [6].

In August 2026 the FDA sent warning letters to four peptide sellers [7]. According to a law-firm analysis of the letters, every seller used a research-use-only or not-for-human-consumption disclaimer, and the FDA set those aside. It relied instead on the sellers’ websites: the claims made, and the sale of reconstitution supplies such as bacteriostatic water alongside the peptides [7].

Compounding: 503A and 503B

The US has a legal middle ground that the UK handles through specials: pharmacy compounding. Two sections of federal law matter [8].

The FDA is explicit that compounded drugs are not FDA-approved, meaning it does not check their safety, effectiveness or quality before they are marketed [8].

A 503A pharmacy can’t compound with any ingredient it likes. The bulk substance must meet a US Pharmacopeia monograph if one exists; failing that, be a component of an FDA-approved drug; failing that, appear on the 503A bulks list [12]. While nominated substances are reviewed, the FDA sorts them into categories. Category 2 is for substances that may present significant safety risks [9].

Where peptides sit now

BPC-157 and several other popular peptides spent years in Category 2. For BPC-157 the FDA cited possible immune reactions, impurities that are hard to characterise, and little or no safety information [9]. In April 2026 the FDA announced that 12 peptides were coming out of Category 2 because their nominations had been withdrawn [10]. The FDA’s Category 2 page, last updated in April 2026, now lists BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, Semax, Epitalon and others as withdrawn, while GHRP-2, GHRP-6, ipamorelin and kisspeptin-10 remain [9].

Leaving Category 2 is not the same as being allowed. Removal does not, by itself, put a substance on the 503A bulks list [10]. An FDA advisory committee voted in July 2026 to recommend six of seven peptides for that list, but the vote changed no law. As one law firm put it in August, those peptides “still cannot be lawfully compounded” until the FDA completes rulemaking or Congress changes the statute [11]. We cover that vote in a separate explainer.

What this means for you

• A research-use-only label tells you nothing about quality. Licensed medicines and 503B products must meet manufacturing standards; research chemicals don’t have to.
• It isn’t a safety statement either. The phrase exists to keep a product outside the system that checks safety.
• In both countries the legal risk falls mainly on sellers and suppliers, but the physical risk falls on whoever injects the product.

What we still don’t know

• When, or whether, the FDA will propose adding any of the six recommended peptides to the 503A bulks list.
• How the MHRA will treat specific peptides that are sold only as research chemicals with no health claims. Classification is case by case, and we have not found a published MHRA determination on BPC-157 or TB-500.
• Whether the August 2026 warning letters signal a wider US enforcement push or a handful of test cases.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.